- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
VIDEO: Susan Urba, MD, Discusses Chemotherapy-Induced Nausea and Vomiting
Susan Urba, MD, Medical Director, Symptom Management & Supportive Care Program, University of Michigan, says that treatment-related factors used to stratify patients to prevent chemotherapy-induced nausea and vomiting are the actual chemotherapy drugs.
Susan Urba, MD, Medical Director, Symptom Management & Supportive Care Program, University of Michigan, says that treatment-related factors used to stratify patients to prevent chemotherapy-induced nausea and vomiting are the actual chemotherapy drugs. Dr Urba says that there are specific lists of medications that breakdown the medications into categories, such as highly emetogenic and moderately emetogenic. Dr Urba uses the medication cisplatin as an example of one of the widely used, highly emetogenic treatments used.
This video was taken on November 9 at the NAMCP Fall Managed Care Forum in Las Vegas, NV.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
